Stock Market & Financial Investment News

Northwest Biotherapeutics reaffirms DCVax-Direct clinical trial interim dataNorthwest Biotherapeutics announced that it refuted Adam Feuerstein's "latest false headline and attack on the company", reaffirming the company's recent interim data announcements from its Phase I/II clinical trial of DCVax-Direct for all inoperable solid tumors. The company added, "The Company's DCVax-Direct trial is ongoing. Contrary to Feuerstein's sensationalized false headline, the Company has not received a 'rebuke' from any clinical trial site, nor does the Company believe there is any basis for any such 'rebuke.' The company has consistently said that it would release interim data on an ongoing basis during the course of its DCVax-Direct Phase I/II trial. This trial is a single-arm, unblinded, 'open label; trial, meaning that all of the patients in the trial are receiving the DCVax-Direct treatment, and the clinical results in patients are visible to the Company as the trial goes along.